| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dichloroacetate (DCA) is a metabolic modulator that targets the altered metabolic state of cancer cells by inhibiting PDKs. This action impacts several key pathways: • Reversal of the Warburg effect • Restoration of mitochondrial function and promotion of apoptosis • suppresses glycolysis and promotes oxidative phosphorylation, thereby increasing mitochondrial ROS-mediated apoptosis in tumor cells • Increase in ROS production leading to oxidative stress • Inhibition of cell cycle progression • Modulation of HIF-1α signaling: DCA might decrease HIF-1α stabilization, thereby reducing the expression of genes that support glycolysis, angiogenesis, and survival under low-oxygen conditions. -DCA has been primarily used in treating congenital lactic acidosis—a rare genetic disorder characterized by the buildup of lactic acid in the body. -DCA is an anti-diabetic and lipid-lowering drug, as well as treating myocardial and cerebrovascular ischemia. -Do not add DCA to hot or warm beverages. DCA is unstable at higher temperatures -Caffeinated increases effectiveness -Vitamin B1 reduces neuropathy (500mg-2500mg/day) -Possibly 20 grams of citric acid 20 minutes before taking DCA -Procaine, Diclofenac or Sulindac to increase SMCT1 -Omeprazole 80mg/day to increase DCA effectiveness -Scorpion venom to increase DCA effectiveness -Metformin 1000mg to 1500mg/day -Propranolol (Ref.) -Fenbendazole shows strong synergy when combined to DCA, So it may make very much sense to combine the two. "Note: DCA is not tumor cell specific,> and therefore the same shift in glucose metabolism that occurs in cancer cells will also take place in immune cells, leading to induction of Tregs (Ref.). In order to avoid this possibility, while using DCA I would also use Treg inhibitors such as Cimetidine (Ref.) or low dose Cyclophosphamide (Ref.)." Dose: 10mg/kg/day and increase slowly to about 25mg/kg/day:(1/2morn,1/2evening) take 5 days on, 2 off? OR 2wks on/ 1wk off: https://www.thedcasite.com/dca_dosage.html Done by mixing it in water and drinking, suggested that DCA not be taken on an empty stomach. **** DCA-induced apoptosis in cancer cells requires sodium-coupled monocarboxylates transporter SLC5A8 (SMCT1) -Inhibitors of DNA methylation induce reactivation of SLC5A8 -Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. -SMCT1 was found to be stimulated by some other NSAIDs (diclofenac, meclofenamate and sulindac), by activin A143 and by the probiotic Lactobacillus plantarum. SMCT1 has been found to be inhibited by some NSAIDs (ibuprofen, ketoprofen, fenoprofen, naproxen135 and indomethacin94), phytochemicals (resveratrol and quercetin) **** Hence these should be avoided with DCA. (also AVOID Bromide, iodide and sulfite ) **** GSTZ1 an/or chloride anion transport inhibitors also reduce resistance to DCA (if the tumor expresses GSTZ1 and contains a high chloride anions level, the GSTZ1 will be stable, maintaining the resistance to DCA). -Dichloroacetate-dca-treatment-strategy GSTZ1 an/or chloride anion transport inhibitors. . -Etacrynic acid is a Cl(-)-ATPase inhibitor -Lansoprazole and Omeprazole inhibit chloride channels. -Chlorotoxin found in scorpion venom (see my post on scorpion venom) can also inhibit chlorine channels Sources: https://northernhealthproducts.com/shop/ https://www.dcalab.com/
|
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 5196- | DCA, | Dichloroacetate induces apoptosis in endometrial cancer cells |
| - | in-vitro, | Var, | NA |
| 5195- | DCA, | Rad, | Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | EMT6 |
| 4901- | DCA, | Sal, | Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer |
| - | Review, | NSCLC, | NA |
| 1881- | DCA, | Chemo, | Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report |
| - | in-vitro, | NA, | HT1080 | - | in-vitro, | NA, | WI38 | - | Case Report, | Var, | NA |
| 1875- | DCA, | Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells |
| - | in-vitro, | neuroblastoma, | NA | - | in-vivo, | NA, | NA |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1864- | DCA, | MET, | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 1868- | DCA, | MET, | Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy |
| - | Case Report, | NA, | NA |
| 1888- | VitB1/Thiamine, | DCA, | High Dose Vitamin B1 Reduces Proliferation in Cancer Cell Lines Analogous to Dichloroacetate |
| - | in-vitro, | PC, | SK-N-BE | - | NA, | PC, | PANC1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:288 Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid